Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study.

What Was Tested

This observational study looks at Vitamin D, K2, Magnesium and Zinc.

To investigate the mechanisms mediating the adverse effects of cholesterol in CIS and to determine the role of the nexus between the vitamin D3 (D3) and cholesterol pathways.

Who Took Part

The study group was 172 patients.

The age groups tagged for this paper are adults, both men and women.

Serum samples were obtained prior to any treatment from study subjects.

Serum obtained prior to any treatment from 172 CIS patients enrolled in a multi-center, prospective, longitudinal study (119 females: 53 males, age: 28.1 ± SD 8.1 years) were analyzed for high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein AI (ApoAI), ApoAII, ApoB, ApoE, and lipoprotein-a.

How the Study Was Run

Multi-center, prospective, longitudinal prospective study.

University hospital multiple sclerosis centers.

Levels of 25-hydroxy vitamin D3 (25(OH)D3), 1,25-dihydroxy D3, and 24,25-dihydroxy D3 were measured using liquid chromatography-mass spectrometry.

What Was Measured

The subject headings attached to it are Cholesterol, Cholesterol, HDL, Cholesterol, LDL, Longitudinal Studies, Multiple Sclerosis, Prognosis and Syndrome.

Author keywords: Clinically isolated syndromes, Environmental factor, Interactions, Lipid and Vitamin D.

What This Means in Plain Language

This is an observational study of Vitamin D, K2, Magnesium and Zinc in 172 patients.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (The Journal of steroid biochemistry and molecular biology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.